Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Show more

Location: 6000 Shoreline Court, South San Francisco, CA, 94080, United States | Website: https://www.veracyte.com | Industry: Diagnostics & Research | Sector: Healthcare


Market Cap

1.977B

52 Wk Range

$19.73 - $47.32

Previous Close

$25.24

Open

$25.31

Volume

319,762

Day Range

$24.87 - $25.62

Enterprise Value

1.88B

Cash

287.4M

Avg Qtr Burn

N/A

Insider Ownership

0.54%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date